Should The FDA Reject Itself? Should The FDA Reject Itself?

Should The FDA Reject Itself‪?‬

    • 5.0 • 1 Rating
    • $10.99
    • $10.99

Publisher Description

This book explores the pharmaceutical industry, the U.S. Food and Drug Administration, and the practice of medicine, with an eye toward questioning the assumptions that many people hold.

Like many readers, I grew up believing that government agencies protect us in the same ways that our parents protected us when we were young; they understand the world well, know us well, and put our interests before their own. But later, I began to question that view: why would a huge government agency manned by people who are complete strangers to me care so much about my well-being? Even if those people do care, do they have the right information to make good decisions about my health and welfare? Do they know anything about me? What if my childhood assumptions were wrong?

One day, I started to reconsider the topic of drug regulation with fresh eyes. That thinking led slowly, but directly, to this book. Instead of simply holding the common view that the current form of regulation is optimal, I started from first principles and questioned the common view. The more I thought about the issue, the more I saw both the benefits and the costs of drug regulation. As I continued to think more keenly, the less I saw the benefits and the more I saw the costs. The result of those years of thinking: this book.

This book explores the issues from first principles. What does drug safety mean? What does drug efficacy mean? Is the FDA scientific? Why do pharmaceutical and biotechnology companies develop new drugs? What could stop them? What could help them? What is the FDA’s role in this? How do patients and their physicians make therapy decisions? Do they share goals with the FDA? What health risks do American face? Why and how do bad drugs enter the market? How did the FDA come about? Would Americans be better off with the current FDA, a revised FDA, or no FDA at all? What laws could be changed to improve the situation?

It's true that I’m an industry insider. But don’t for a minute think that I’m an industry shill. This book doesn’t repeat industry perspectives; it challenges them.

GENRE
Business & Personal Finance
RELEASED
2021
November 29
LANGUAGE
EN
English
LENGTH
555
Pages
PUBLISHER
Chicago Park Press
SELLER
Chicago Park Press
SIZE
39
MB

More Books Like This

Inside the FDA Inside the FDA
2010
Drug Approvals and Deadly Delays. Drug Approvals and Deadly Delays.
2010
Off-label Prescribing Off-label Prescribing
2014
Pharma and Profits Pharma and Profits
2022
The FDA should Not Mandate Comparative-Effectiveness Trials (Health Policy Outlook) The FDA should Not Mandate Comparative-Effectiveness Trials (Health Policy Outlook)
2011
It’s All About the Money: The Truth About Orthodox Cancer Treatments It’s All About the Money: The Truth About Orthodox Cancer Treatments
2018

More Books by Charles L. Hooper

Making Great Decisions in Business and Life Making Great Decisions in Business and Life
2006
Would The FDA Reject Itself? Would The FDA Reject Itself?
2021